公开(公告)号：AU8018701A

公开(公告)日：2002-03-13

申请号：AU8018701

申请日：2001-08-27

Applicant: YAMANOUCHI PHARMA CO LTD ,  TORAY INDUSTRIES

Inventor： MORIHIRA KOICHIRO ,  INAMI HIROSHI ,  KUBOTA HIROKAZU ,  YOKOYAMA KAZUHIRO ,  MOROKATA TATSUAKI ,  TAKEUCHI MAKOTO ,  TAKAHASHI TOSHIYA ,  KANEKO MASAYUKI ,  IMAOKA TAKAYUKI ,  TORII YUICHI ,  IURA YOSUKE

IPC: A61P11/06 ,  A61P29/00 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C07D471/08 ,  C07D207/14 ,  A61K31/445 ,  A61K31/4468 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/5377 ,  A61K31/55 ,  C07D211/34 ,  C07D211/46 ,  C07D211/58 ,  C07D211/62 ,  C07D401/06 ,  C07D401/14 ,  C07D403/12 ,  C07D409/12 ,  C07D409/14 ,  C07D451/04

公开(公告)号：AU9227601A

公开(公告)日：2002-04-08

申请号：AU9227601

申请日：2001-09-27

Applicant: TORAY INDUSTRIES

Inventor： TAKAHASHI TOSHIYA ,  IMAOKA TAKAYUKI ,  TOMIOKA HIROKI ,  HATAKEYAMA DAIGO ,  NITTA AIKO ,  KANEKO MASAYUKI ,  TAKIZAWA SATOKO ,  TORII YUICHI ,  MORIHIRA KOICHIRO ,  MOROKATA TATSUAKI

IPC: A61K31/445 ,  A61K31/4725 ,  A61K31/497 ,  A61K31/506 ,  A61P29/00 ,  A61P37/08 ,  A61P43/00 ,  C07D401/06 ,  C07D211/14 ,  A61K31/454 ,  A61K31/496 ,  A61K31/513 ,  A61K31/551 ,  C07D217/06 ,  C07D239/10 ,  C07D243/08 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D471/04 ,  C07D487/08

公开(公告)号：CA2319435A1

公开(公告)日：2000-06-15

申请号：CA2319435

申请日：1999-12-03

Applicant: TORAY INDUSTRIES

Inventor： TANIDA KOH ,  KANEKO MASAYUKI ,  IMAOKA TAKAYUKI ,  TORII YUICHI ,  MORI NORIKO ,  TAKAHASHI TOSHIYA

IPC: A61K31/437 ,  A61K31/4545 ,  A61K31/4745 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/53 ,  A61P29/00 ,  A61P43/00 ,  C07D239/70 ,  C07D471/04 ,  C07D487/00 ,  C07D487/04 ,  C07D515/00

Abstract: Novel triazolo derivatives including the one represented by formula (26), and pharmacologically acceptable salts thereof; and chemokine inhibitors containing the same as the active ingredient. These compounds are useful as remedies for allergic diseases including bronchial asthma and atopic dermatitis, inflammatory diseases including rheumatoid arthritis, and autoimmune diseases including nephritis and ulcerative colitis, or anti-AIDS drugs.

公开(公告)号：EP1067130A4

公开(公告)日：2004-02-11

申请号：EP99957410

申请日：1999-12-03

Applicant: TORAY INDUSTRIES ,  MORI NORIKO ,  KANEKO MASAYUKI ,  TORII YUICHI

Inventor： MORI NORIKO ,  KANEKO MASAYUKI ,  TORII YUICHI ,  TAKAHASHI TOSHIYA ,  IMAOKA TAKAYUKI ,  TANIDA KOH

IPC: A61K31/437 ,  A61K31/4545 ,  A61K31/4745 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/519 ,  A61K31/53 ,  A61P29/00 ,  A61P43/00 ,  C07D239/70 ,  C07D471/04 ,  C07D487/00 ,  C07D487/04 ,  C07D515/00

CPC classification number: A61K31/437 ,  A61K31/4545 ,  A61K31/497 ,  C07D471/04 ,  Y02P20/582

Abstract: Novel triazolo derivatives including the one represented by formula (26), and pharmacologically acceptable salts thereof; and chemokine inhibitors containing the same as the active ingredient. These compounds are useful as remedies for allergic diseases including bronchial asthma and atopic dermatitis, inflammatory diseases including rheumatoid arthritis, and autoimmune diseases including nephritis and ulcerative colitis, or anti-AIDS drugs.

公开(公告)号：JP2002187880A

公开(公告)日：2002-07-05

申请号：JP2001293350

申请日：2001-09-26

Applicant: TORAY INDUSTRIES ,  YAMANOUCHI PHARMA CO LTD

Inventor： TAKAHASHI TOSHIYA ,  IMAOKA TAKAYUKI ,  TOMIOKA HIROKI ,  HATAKEYAMA DAIGO ,  NITTA AIKO ,  KANEKO MASAYUKI ,  TAKIZAWA SATOKO ,  TORII YUICHI ,  MORIHIRA KOICHIRO ,  TAKARAKATA TATSUAKI

IPC: C07D217/06 ,  A61K31/445 ,  A61K31/454 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/513 ,  A61K31/551 ,  A61P11/02 ,  A61P11/06 ,  A61P17/04 ,  A61P17/06 ,  A61P29/00 ,  A61P37/08 ,  A61P43/00 ,  C07D211/14 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/06 ,  C07D413/14 ,  C07D451/02

Abstract: PROBLEM TO BE SOLVED: To prevent and treat allergic inflammation diseases caused by leukergy of lymphocyte, eosinocyte, basophilic leukocyte and the like by providing CCR3 inhibitor. SOLUTION: This nitrogen-containing compound is represented by formula I (l is an integer of 0-2; m is an integer of 0-5; Ar is, for example, an aryl group such as 2-1,2,3,4-tetrahydroisoquinoly, phenyl, pyridyl group or the like; A is a nitrogen-containing bifunctional group such as CONH or the like; B is, for example, 4-(diphenyl methyl)piperidino or the like) or its pharmaceutical acceptable salt. This CCR3 inhibitor comprises the nitrogen-containing compound as an active ingredient.